Lachesis Biosciences Limited: Low-Risk Alzheimer’s Drug Development?

Lodge Corporate is currently conducting public capital raising for the unlisted Lachesis Biosciences Limited. It an unusual raising in that it lets retail investors purchase shares in an investment normally only open to institutions and high net worth individuals. As such, it allows retail investors to get in on the ground floor and participate in the uplift in value (~+30%) that Initial Public Offerings (IPOs) often bring, due to the liquidity premium associated with being a public company bring. Lachesis intends to list in the 3rd quarter of calendar 2017. The prospectus for the offering can be found here.

Read More

Biotech Can Play A Meaningful Role In Your Portfolio

It was 1999 and I had just purchased my first equity on the Australian Stock Exchange (ASX); 1,000 Biota Holdings (BTA) at $4.22 a share. The stock had fallen heavily after a US Food and Drug Administration (FDA) advisory committee (AdCom) had recommended the FDA issue GlaxoSmithKline (GSK) a “Not Approvable” letter for its influenza drug, zanamivir (Relenza). GSK had licensed zanamivir from Biota in 1990 and Biota would receive a windfall should this blockbuster drug make it to market, or so we believed.

Read More